sign in sign up
<<
Home , Brentuximab vedotin, Enfortumab vedotin, Trastuzumab, Trastuzumab deruxtecan

INVESTOR FACT SHEET MARCH 2021

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. We are focused on developing first-in-class or best-in-class medicines that address unmet medical needs and improve treatment outcomes for patients. ADCETRIS® () and PADCEV® (- ejfv) use the company’s industry-leading antibody-drug conjugate (ADC) technology designed to bring a powerful medicine directly to cancer cells. ADCETRIS is approved in certain CD30-expressing , and PADCEV is approved in certain metastatic urothelial cancers. TUKYSA® (), a small molecule inhibitor, is approved in certain HER2-positive metastatic breast cancers. We are also advancing a pipeline of novel therapies for solid tumors and blood-related cancers.

ADCETRIS: Expanding Global Brand TUKYSA: Approved in the U.S. in 2020 Nasdaq Symbol: SGEN in Blood-related Cancers Followed by Approval in E.U. and Great • ADCETRIS is approved in the U.S. for six indications Britain in Early 2021 Employees: >2,100 worldwide including frontline Stage 3 and 4 Hodgkin • TUKYSA was approved in combination with other Management: (HL) and CD30-expressing peripheral T-cell lymphomas agents in previously treated metastatic HER2-positive (PTCL); commercially available in 75 countries with , including patients with brain metastases. Clay Siegall, Ph.D., President, global sales exceeding $1.1 billion in 2020. CEO & Chairman • Ongoing development program in earlier stages • commercializes in the U.S. and Canada; of breast cancer as well as other HER2-positive Todd Simpson, CFO Takeda in the rest of world. cancers, including colorectal cancer. Roger Dansey, M.D., CMO PADCEV: Strong Product Launch, with Net • In 2020, Seagen granted Merck an exclusive Headquarters / European Office: Sales of $222M in First Year of Commercialization; license to commercialize TUKYSA outside of the U.S., Canada and Europe. Potential Label Expanding Trials Ongoing Bothell, WA USA / Zug, Switzerland • In February 2021, we and our partner Astellas Tisotumab Vedotin Commercial Products: submitted two sBLAs to the FDA seeking to convert • We and our partner Genmab submitted a BLA to ADCETRIS® (brentuximab vedotin) accelerated approval to regular approval and to the FDA seeking accelerated approval for metastatic ® expand the current label in previously treated cervical cancer based on positive pivotal trial results. PADCEV (enfortumab vedotin-ejfv) metastatic urothelial cancer (mUC). TUKYSA® (tucatinib) • Clinical trials ongoing in first-line mUC and earlier Ladiratuzumab Vedotin stages of bladder cancer as well as in a range of • In 2020, we entered into global co-development

QUICK FACTS FY 2020 AS OF 12/31/2020: other solid tumors. and co-commercialization agreement with Merck for Product Revenues: $1.0 billion LV in breast cancer and other solid tumors. Seagen received $600 million upfront and is eligible for Total Revenues: $2.2 billion progress-dependent milestone payments up to $2.6 R&D Expenses: $827 million billion. Additionally, Merck made a $1 billion equity Cash: $2.7 billion investment in Seagen. Shares Outstanding: ~181 million

To learn more about us, please visit www.seagen.com Twitter @SeagenGlobal CLINICAL DEVELOPMENT PIPELINE

Program Tumor Type Setting Trial Name/Description Phase 1 Phase 2 Phase 3 Diffuse large B-cell lymphoma R/R + lenalidomide, * (HL) 1L + , and

ADCETRIS® HL or PTCL (unfit for combination ) 1L Monotherapy (Brentuximab HL and PTCL R/R Retreatment vedotin) HL (pediatrics) R/R CheckMate 744: + nivolumab PTCL (< 10% CD30 expression) 1L + cyclophosphamide, doxorubicin and Metastatic solid tumors R/R + post PD-1 1L EV-302: + pembrolizumab vs chemotherapy alone * EV-301: Post PD(L)-1 and post platinum chemotherapy SUBMITTED FOR APPROVAL Locally advanced or metastatic urothelial cancer * EV-201: Cohort 2 post PD(L)-1, platinum naive and cisplatin ineligible SUBMITTED FOR APPROVAL ® * PADCEV 1L/2L EV-103: +/- pembrolizumab (Enfortumab vedotin-ejfv) 1L EV-303/KEYNOTE-905: + pembrolizumab, cisplatin ineligible * Muscle invasive bladder cancer EV-304/KEYNOTE-B15: + pembrolizumab, cisplatin eligible * 1L EV-103: +/- pembrolizumab Locally advanced or metastatic solid tumors EV-202: Monotherapy HER2+ 1L/2L HER2CLIMB-02: + T-DM1 * High risk HER2+ breast cancer CompassHER2 RD** * HER2+ metastatic breast cancer + deruxtecan TUKYSA® HER2+ metastatic colorectal cancer R/R MOUNTAINEER: + trastuzumab (Tucatinib) * HER2+ gastroesophageal cancer 2L MOUNTAINEER-02: + trastuzumab, and chemotherapy * Metastatic solid tumors HER2 alterations + trastuzumab, +/- fulvestrant HER2+ gastric cancer 1L + trastuzumab, oxaliplatin 2L/3L innovaTV 301: Monotherapy * Metastatic/recurrent cervical cancer 2L/3L innovaTV 204: Monotherapy BLA SUBMITTED 1Q21 * Tisotumab 1L/2L innovaTV 205: + other anti-cancer agents vedotin Locally advanced solid tumors innovaTV 206 (Japan only) Metastatic solid tumors R/R innovaTV 207: Monotherapy Platinum-resistant 2L innovaTV 208: Monotherapy Metastatic breast cancer R/R Monotherapy Ladiratuzumab Metastatic triple-negative breast cancer 1L + pembrolizumab vedotin Metastatic solid tumors R/R Monotherapy SGN-CD228A Solid tumors R/R Monotherapy SGN-B6A Solid tumors R/R Monotherapy SGN-STNV Solid tumors R/R Monotherapy SEA-BCMA Multiple myeloma R/R +/- SEA-CD40 Pancreatic cancer R/R +/- pembrolizumab, gemcitabine, nap-paclitaxel SEA-CD70 MDS / AML R/R Monotherapy SEA-TGT Solid tumors and lymphoma R/R +/- pembrolizumab

1L: front/first-line 2L: second-line 3L: third-line R/R: relapsed/refractory PTCL: Peripheral T-cell lymphoma * Registrational intent ** Conducted in collaboration with Alliance for Clinical Trials in Oncology and National Cancer Institute (NCI) © 2021 Seagen Inc. Bothell, WA 98021. All rights reserved. ADCETRIS, TUKYSA, Seagen and are U.S. registered trademarks of Seagen Inc. PADCEV is a trademark owned by Agensys, Inc. and Seagen Inc. EUM/COR/2020/0024 ADVANCING TARGETED THERAPIES FOR CANCER: ADC TECHNOLOGY AND BEYOND

Targeting the ADCs harness the specificity of monoclonal outside of the cell: antibodies and the potency of cytotoxic agents • Sugar-engineered antibodies (SEA) Antibody-Drug Extending Our Opportunities Through ADC Technology Collaborations Conjugates (ADCs) Activating Beyond the broad internal development of our ADCs, we have entered into collaborations immune cells: • Sugar- with a number of biotechnology and pharmaceutical companies. These license agreements Targeting signaling engineered have generated hundreds of millions of dollars to date in development and regulatory pathways inside antibodies (SEA) the cell: CANCER IMMUNE milestones. Additionally, we are receiving royalties on worldwide net sales of two ap- • Small molecule CELL CELL proved ADC products. In 2019, , a member of the Roche Group, received U.S. TKIs and European Union (EU) approval for Polivy® (), an ADC that uses our technology, for the treatment of relapsed/refractory diffuse large B-cell lymphoma. In 2020, GlaxoSmithKline received approval in the U.S. and EU for Blenrep® (), another ADC using our technology, for the treatment of multiple myeloma.

Various combinations of these novel modalities are likely to be the future of treatment in oncology

Potential to Improve Patient Outcomes through Our ADC technology is employed in our approved Advancing a Pipeline of Potentially Differentiated Multiple Approaches to Targeted Therapies products ADCETRIS and PADCEV, as well as in several Cancer Therapies pipeline programs. We are developing highly-specific targeted therapies that Our early-stage clinical pipeline includes seven programs provide multiple approaches for the . targeted to various cancers. These include ADCs and These include agents that are directed toward receptors on Targeting Pathways Inside the Cell empowered antibodies designed to be first-in-class or the outside of cells, the signaling pathways within the cell, Certain signaling pathways in the cell are known to be in- best-in-class therapies that address significant unmet and the activation of immune cells. These agents may be volved in initiation and progression of cancer. For instance, needs for cancer patients. used as single agents, or as part of combination regimens. the kinase signaling pathway has been shown to drive many aspects of cancer tumor biology including survival, Targeting Outside of the Cell motility and evasion of antitumor immune response. TUKYSA, an oral tyrosine kinase inhibitor, is approved in Investor and Media Contact: Our industry-leading antibody-drug conjugate technology the U.S., EU and several other countries. combines the specificity of monoclonal antibodies, inno- Peggy Pinkston vative linker systems, and the power of potent cell-killing 425.527.4160 Activating Immune Cells agents to treat cancer. [email protected] Immunogenic cell death induced by ADCs can result in In our ADCs, stable linkers attach a potent synthetic the stimulation and recruitment of an immune response cell-killing (cytotoxic) agent to an antibody. The antibody toward cancer. We believe these properties could make is targeted against a specific tumor-associated receptor our vedotin-based ADCs a preferred partner for immu- on cancer cell surfaces. Our linker systems release the no-oncology agents, such as checkpoint inhibitors. We cytotoxic agent once inside the targeted cells. By targeting are currently conducting several clinical trials combining specific tumor-associated receptors on the surface of ADCs with checkpoint inhibitors. cancer cells, ADCs have the potential to spare non-target- ed cells and reduce toxic side effects resulting in better © 2021 Seagen Inc. Bothell, WA 98021. All rights reserved. ADCETRIS, TUKYSA, outcomes for patients. Seagen and are U.S. registered trademarks of Seagen Inc. PADCEV is a trademark owned by Agensys, Inc. and Seagen Inc.

USM/COR/2020/0032